NCT06052852 2025-11-17Study of BDC-3042 as Single Agent and in Combination With Cemiplimab in Patients With Advanced MalignanciesBolt Biotherapeutics, Inc.Phase 1 Terminated17 enrolled
NCT05429866 2023-03-08Immunological Variables Associated to ICI Toxicity in Cancer PatientsJules Bordet InstitutePhase 2 Unknown441 enrolled